DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001


Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: May 1, 2020

Detailed Description

This retrospective study is intended to provide large-scale, real-world data on clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.


  • Drug: DEXYCU (dexamethasone intraocular suspension) 9%.
    • DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).

Arms, Groups and Cohorts

  • DEXYCU (dexamethasone intraocular suspension) 9%.
    • DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Eyes With Anterior Chamber Cell Grade 0
    • Time Frame: Postoperative day 8
    • Of eyes with a record at postoperative day 8, percentage with anterior chamber cell grade 0. Cells in the anterior chamber of the eye are indicative of intraocular inflammation and are evaluated using a slit-lamp biomicroscope; a grade of 0 indicates that no inflammatory cells were visible in a 1 mm by 1 mm slit beam.

Participating in This Clinical Trial

Inclusion Criteria

  • Male and Female subjects at least 18 years of age – Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received DEXYCU Exclusion Criteria • Subjects who underwent cataract surgery and did not receive DEXYCU

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • EyePoint Pharmaceuticals, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Dario Paggiarino, MD, Principal Investigator, Senior Vice President, Chief Medical Officer, EyePoint Pharmaceuticals
    • Keyur Patel, PharmD, Study Chair, Vice President, Medical Affairs, EyePoint Pharmaceuticals
    • Flavio Leonin, Jr., MD, Study Director, Senior Manager, Clinical Affairs, EyePoint Pharmaceuticals

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.